GlassScriptPhysician profile
Denise C Ginart
NPI 1205915014
$9,216.09
in general payments reported to CMS, 2019-2025
45 companies · $1,775 in 2025
The $1,775 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,323 · 2020: $896 · 2021: $994 · 2022: $1,223 · 2023: $1,507 · 2024: $1,497 · 2025: $1,775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,614 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,613.72 |
| Education | $165.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $976.87 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $819.99 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $799.26 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Astrazeneca Pharmaceuticals LP | $786.14 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $772.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $579.94 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Lilly USA, LLC | $547.39 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $440.48 | 2019-2025 | Veozah |
| Abbott Laboratories | $401.22 | 2020-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $379.11 | 2019-2025 | |
| Amgen INC. | $343.63 | 2019-2025 | Evenity, Repatha, Prolia |
| Abbvie INC. | $300.26 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $230.65 | 2019-2024 | Trintellix |
| Sanofi Pasteur INC. | $152.42 | 2019-2023 | |
| Dexcom, INC. | $150.43 | 2022-2025 | Dexcom G6 Transmitter |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Ginart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.